Laboratory organisation and management of SARS-CoV-2 infection in Niger, West Africa
Because the coronavirus illness 2019 (COVID-19) pandemic unfolds, laboratory providers have been recognized as key to its containment. This text outlines the laboratory organisation and administration and management interventions in Niger.
The capitol metropolis of Niger, Niamey, adopted a ‘Nationwide COVID-19 Emergency Preparedness and Response Plan’ to strengthen the preparedness of the nation for the detection of extreme acute respiratory syndrome coronavirus-2. Laboratory coaching and diagnostic capability constructing had been supported by present lively medical and analysis laboratories for extra fast and practicable responses. The Nationwide Reference Laboratory for Respiratory Viruses positioned on the Centre de Recherche Médicale et Sanitaire was designated because the reference centre for COVID-19 testing. The nationwide plan for COVID-19 testing is being steadily adopted in different areas of the nation in response to the quickly evolving COVID-19 emergency and to make sure a extra fast turn-around time.
 After the decentralisation of COVID-19 testing to different areas of the nation, turn-around occasions had been decreased from 48-72 h to 12-24 h. Decreasing turn-around occasions allowed Niger to scale back the size of sufferers’ stays in hospitals and isolation amenities. Shortages in testing capability should be anticipated and addressed. In an effort to scale back threat of shortages and improve availability of reagents and consumables, Niamey diversified real-time reverse transcriptase-polymerase chain response kits for extreme acute respiratory syndrome coronavirus-2 detection.
Within the period of evidence-based medication, haematological reference intervals are important for the interpretation of information for medical decision-making, monitoring of remedy and analysis. It’s not unusual that reference intervals utilized in most African nations have been obtained from revealed scientific literature, textbooks, reagent/instrument manuals.

Design of Purposeful Nanoparticles for Intractable Illness Remedy

Protein affinity reagents are extensively used for primary analysis, diagnostics, and illness remedy. Antibodies and their fragments are often called the most typical protein affinity reagents. They particularly and strongly bind to focus on molecules and inhibit their features. Thus, antibody medication have elevated within the latest 20 years for illness remedy, similar to most cancers.
These sturdy protein-protein interactions are composed of a nexus of a number of weak interactions. Artificial polymers that bind to focus on molecules have been developed by the imitation of protein-protein interactions. These polymers present nanomolar affinity for the goal and neutralize their features; thus, they’re of serious curiosity as an economical protein affinity reagent. We now have been growing artificial polymer nanoparticles (NPs) that bind to focus on peptides and proteins by the inclusion of a number of useful monomers, similar to charged and hydrophobic monomers. On this evaluate, the main focus is on the design of artificial polymer NPs that bind to focus on molecules for illness remedy. We succeeded in neutralization of poisonous peptides and signaling proteins each in vitro and in vivo. Moreover, linear polymers had been modified on a lipid nanoparticle floor to enhance polymer biodistribution. Our latest findings ought to present helpful data for the event of abiotic protein affinity reagents.
The purpose of the examine was to judge of the results of glycerol and DMSO, belonging to the endocellular kind of cryoprotective brokers (CPAs), in addition to polyethylene glycol, dextran, sucrose, and mannitol, associated to exocellular CPAs, on proteins of the membrane-cytoskeleton complicated (MCC) of human erythrocytes on the stage previous freezing. The evaluation of protein modifications was carried out by SDS-PAGE utilizing totally different approaches when making ready samples for evaluation. Using β-mercaptoethanol within the solubilizing buffer confirmed no modifications within the MCC polypeptide profile of erythrocytes preincubated with CPAs thus suggesting good biocompatibility of the studied substances.
Using the cross-linking reagent diamide for evaluation of protein modifications didn’t reveal structural abnormalities that will end in vital modifications within the localization of -SH teams and a rise within the manufacturing of high-molecular-weight polypeptide complexes recognized by SDS-PAGE with out β-mercaptoethanol. Nonetheless, the acknowledged modifications within the electrophoretic mobility of proteins within the space of band 5 in erythrocytes incubated with CPA within the presence of diamide counsel a reorganization of the structural state of actin protofilaments, which could be attributable to alterations of actin monomers themselves or initiated by modifications of actin-binding proteins within the presence of CPAs.
 Laboratory organisation and management of SARS-CoV-2 infection in Niger, West Africa

Technology of Keratinocytes from Human Induced Pluripotent Stem Cells Underneath Outlined Tradition Circumstances

Differentiation of keratinocytes from human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs) has develop into an necessary instrument for wound therapeutic analysis and for learning pores and skin illnesses in situations the place affected person cells usually are not out there. A number of keratinocyte differentiation protocols utilizing hiPSC colony fragments or embryoid our bodies have been revealed with some requiring extended time for differentiation or prolonged use of reagent cocktails.
On this examine, we current a simplified technique to effectively generate massive numbers of uniformly differentiated keratinocytes in lower than Four weeks from singularized hiPSCs with differentiation components, retinoic acid and bone morphogenetic protein 4 (BMP4).
Low seeding density of singularized iPSCs ends in keratinocyte cultures with minimal cell dying throughout differentiation and as much as 96% homogeneity for keratin 14-positive cells and low share of keratinocyte maturation markers, akin to early passage major keratinocytes. hiPSC-derived keratinocytes stay in a proliferative state, could be maintained for extended durations of time, and could be terminally differentiated underneath excessive calcium circumstances in the identical means as major human keratinocytes.

Rat PlGF

MBS691603-0002mg 0.002mg
EUR 265

Rat PlGF

MBS691603-5x0002mg 5x0.002mg
EUR 890

Anti-Human PGF/PlGF/PLGF Nanobody

MBS1568114-01mg 0.1mg
EUR 405

Anti-Human PGF/PlGF/PLGF Nanobody

MBS1568114-5x01mg 5x0.1mg
EUR 1520

Rat PlGF-1

RC333230 25 µg Ask for price

Recombinant Rat PLGF

MBS7610678-005mg 0.05mg
EUR 345

Recombinant Rat PLGF

MBS7610678-02mg 0.2mg
EUR 635

Recombinant Rat PLGF

MBS7610678-1mg 1mg
EUR 1800

Recombinant Rat PLGF

MBS7610678-5x1mg 5x1mg
EUR 6955

Rat PLGF ELISA Kit

ERP0025 96Tests
EUR 625.2

Rabbit anti PlGF (human)

102-PA04AG 50ug
EUR 240

Rabbit anti PlGF (human)

102-PA04S 100ug
EUR 240

RABBIT ANTI HUMAN PLGF

MBS222860-01mg 0.1mg
EUR 660

RABBIT ANTI HUMAN PLGF

MBS222860-5x01mg 5x0.1mg
EUR 2795

Anti-Human PlGF Antibody

101-M03 100 µg
EUR 378
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-M67 100 µg
EUR 189
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-M69 100 µg
EUR 189
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF Antibody

101-MBi67 50 µg
EUR 189
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Mouse PlGF Antibody

103-M03 100 µg
EUR 399
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF-2 has been identified. Mouse PlGF shares 60%, 92%, 62% and 59% aa identity with the appropriate isoform of human, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during human pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially human PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, like VEGF164/165, shows heparin-dependent binding of neuropilin (Npn)-1 and Npn-2 and can inhibit nerve growth cone collapse. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic P lGF antibodies are being investigated to inhibit tumor growth and angiogenesis.

Anti-Mouse PlGF Antibody

103-PA04AG 50 µg
EUR 157.5
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Anti-Mouse PlGF Antibody

103-PA04S 100 µg
EUR 126
Description: Placenta growth factor (PlGF) is a member of the vascular endothelial growth factor (VEGF) family of growth factors. PlGF and VEGF share primary structural as well as limited amino acid sequence homology with the A and B chains of PDGF. All eight cysteine residues involved in intra and interchain disulfides are conserved among these growth factors. As a result of alternative splicing, three PlGF RNAs encoding monomeric human PlGF1, PlGF2 and PlGF3 isoform precursors containing 149, 179 and 219 amino acid residues, respectively, have been described. In normal mouse tissues, only one mouse PlGF mRNA encoding the equivalent of human PlGF2 has been identified. Mouse PlGF shares 65% amino acid identity with human PlGF2. The gene for PlGF has been mapped to mouse chromosome 12 and human chromosome 14. PlGF binds with high affinity to Flt1, but not to Flk1/KDR.

Anti-Human PlGF Antibody

102-P248 100 µg
EUR 245.7
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Mouse PlGF Antibody

MBS4158465-01mg 0.1mg
EUR 1255

Anti-Mouse PlGF Antibody

MBS4158465-5x01mg 5x0.1mg
EUR 5390

Anti-Human PlGF Antibody

MBS4158489-01mg 0.1mg
EUR 920

Anti-Human PlGF Antibody

MBS4158489-5x01mg 5x0.1mg
EUR 3880

Mouse Anti-Human PlGF

MBS690289-01mg 0.1mg
EUR 430

Mouse Anti-Human PlGF

MBS690289-5x01mg 5x0.1mg
EUR 1645

Mouse Anti-Human PlGF

MBS690834-005mg 0.05mg
EUR 430

Mouse Anti-Human PlGF

MBS690834-5x005mg 5x0.05mg
EUR 1645

Mouse Anti-Human PlGF

MBS691018-01mg 0.1mg
EUR 430

Mouse Anti-Human PlGF

MBS691018-5x01mg 5x0.1mg
EUR 1645

Rabbit Anti-Mouse PlGF

103-PA04 100ug
EUR 240

Rat PlGF Recombinant Protein

R20-061 5 µg
EUR 136.5
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. In rat only one PlGF that is the equivalent of human PlGF-2 has been identified. Rat PlGF shares 60%, 92%, 62% and 59% aa identity with the appropriate isoform of human, mouse, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during human pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially human PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, like VEGF164/165, shows heparin-dependent binding of neuropilin (Npn)-1 and Npn-2 and can inhibit nerve growth cone collapse. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic PlGF antibodies are being investigated to inhibit tumor growth and angiogenesis.

Rat PlGF Recombinant Protein

R20-061S 2 µg
EUR 73.5
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. In rat only one PlGF that is the equivalent of human PlGF-2 has been identified. Rat PlGF shares 60%, 92%, 62% and 59% aa identity with the appropriate isoform of human, mouse, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during human pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially human PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, like VEGF164/165, shows heparin-dependent binding of neuropilin (Npn)-1 and Npn-2 and can inhibit nerve growth cone collapse. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic PlGF antibodies are being investigated to inhibit tumor growth and angiogenesis.

Rat PlGF Recombinant Protein

R20-062 20 µg
EUR 313.95
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF-1), 152 (PlGF-2), and 203 (PlGF-3) amino acids (aa) respectively. Only PlGF-2 contains a highly basic heparin-binding 21 aa insert at the C-terminus. In rat only one PlGF that is the equivalent of human PlGF-2 has been identified. Rat PlGF shares 60%, 92%, 62% and 59% aa identity with the appropriate isoform of human, mouse, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during human pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt-1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2-mediated angiogenesis. However, PlGF (especially human PlGF-1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF-2, like VEGF164/165, shows heparin-dependent binding of neuropilin (Npn)-1 and Npn-2 and can inhibit nerve growth cone collapse. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis. Circulating PlGF often correlates with tumor stage and aggressiveness, and therapeutic PlGF antibodies are being investigated to inhibit tumor growth and angiogenesis.

Anti-Human PlGF-2 Antibody

101-M65 100 µg
EUR 246.75
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-Human PlGF-2 Antibody

101-M65A 100 µg
EUR 246.75
Description: Placenta Growth Factor-2 (PlGF-2), a 22 kDa protein consisting of 152 amino acid residues is produced as a homodimer. PlGF is a polypeptide growth factor and a member of the platelet-derived growth factor family but more related to vascular endothelial growth factor (VEGF). PlGF acts only as a weak mitogen for those cell types possessing receptors for binding (e.g. vascular endothelial cells). At least one high-affinity receptor for PlGF (FLT-1 or VEGF-R1) has been demonstrated in different primary cell types (e.g. human umbilical vein endothelial cells and monocytes). In addition to its action as a weak mitogen it is also a chemoattractant for monocytes and endothelial cells. Three different proteins are generated by differential splicing of the human PlGF gene: PlGF-1 (131aa native chain), PlGF-2 (152aa) and PlGF-3 (203aa). All 3 mitogens are secretable proteins, but PlGF-2 can bind to heparin with high affinity. PlGF is apparently a homodimer, but preparations of PlGF show some heterogeneity on SDS gels depending of the varying degrees of glycosylation. All dimeric forms possess similar biological activities. Heterodimers between VEGF and PlGF are mitogenic for endothelial cells and have strong angiogenic activity in vivo (e.g. in the CAM assay or in the cornea pocket assay). Different cells and tissues (e.g. placenta) express PlGF-1 and PlGF-2 at different rates. A much related protein of PlGF is VEGF with about 53% homology and VEGF-B with similar biological activities.

Mouse Anti-Human PlGF-2

MBS690323-01mg 0.1mg
EUR 450

Mouse Anti-Human PlGF-2

MBS690323-5x01mg 5x0.1mg
EUR 1725

Mouse Anti-Human PlGF-2

MBS692571-01mg 0.1mg
EUR 450

Mouse Anti-Human PlGF-2

MBS692571-5x01mg 5x0.1mg
EUR 1725

PLGF(PLGF93) Antibody

BNC800093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC800093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC800094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF680 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC810093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC810093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC810094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF680R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCA0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), APC conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCA0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), APC conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC610093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC610094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF660R conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC700093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC700094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF770 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCH0093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCH0093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCH0094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCH0094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCP0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), PerCP conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCP0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), PerCP conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCR0093-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF93), RPE conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCR0094-250 250uL
EUR 459.6
Description: Primary antibody against PLGF(PLGF94), RPE conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCAP0093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNCAP0093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCAP0094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNCAP0094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC430093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC430094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF543 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC050093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC050094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF405M conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF93) Antibody

BNC550093-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF93), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-100 100uL
EUR 238.8
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

PLGF(PLGF94) Antibody

BNC550094-500 500uL
EUR 652.8
Description: Primary antibody against PLGF(PLGF94), CF555 conjugate, Concentration: 0.1mg/mL

Anti-Human PGF/PlGF Antibody

MBS1569264-01mg 0.1mg
EUR 375

Anti-Human PGF/PlGF Antibody

MBS1569264-5x01mg 5x0.1mg
EUR 1390

Anti-Human PlGF (native) Antibody

102-PABi04 50 µg
EUR 157.5
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Anti-PGF/Plgf Picoband Antibody

MBS1750586-01mg 0.1mg
EUR 450

Anti-PGF/Plgf Picoband Antibody

MBS1750586-5x01mg 5x0.1mg
EUR 1870

Anti-Human PlGF (Peptide) Antibody

102-PA01S 100 µg
EUR 115.5
Description: Placenta growth factor (PlGF) is a member of the PDGF/VEGF family of growth factors that share a conserved pattern of eight cysteines. Alternate splicing results in at least three human mature PlGF forms containing 131 (PlGF1), 152 (PlGF2), and 203 (PlGF3) amino acids (aa) respectively. Only PlGF2 contains a highly basic heparinbinding 21 aa insert at the C-terminus. In the mouse, only one P lGF that is the equivalent of human PlGF2 has been identified. Human PlGF1 shares 56%, 55%, 74% and 95% aa identity with the appropriate isoform of mouse, rat, canine and equine PlGF. PlGF is mainly found as variably glycosylated, secreted, 55 - 60 kDa disulfide linked homodimers. Mammalian cells expressing PlGF include villous trophoblasts, decidual cells, erythroblasts, keratinocytes and some endothelial cells. Circulating PlGF increases during pregnancy, reaching a peak in mid-gestation; this increase is attenuated in preeclampsia. However, deletion of PlGF in the mouse does not affect development or reproduction. Postnatally, mice lacking PlGF show impaired angiogenesis in response to ischemia. PlGF binds and signals through VEGF R1/Flt1, but not VEGF R2/Flk-1/KDR, while VEGF binds both but signals only through the angiogenic receptor, VEGF R2. PlGF and VEGF therefore compete for binding to VEGF R1, allowing high PlGF to discourage VEGF/VEGF R1 binding and promote VEGF/VEGF R2mediated angiogenesis. However, PlGF (especially PlGF1) and some forms of VEGF can form dimers that decrease the angiogenic effect of VEGF on VEGF R2. PlGF2, but not PLGF-1, shows heparindependent binding of neuropilin (Npn)-1 and Npn2. PlGF induces monocyte activation, migration, and production of inflammatory cytokines and VEGF. These activities facilitate wound and bone fracture healing, but also contribute to inflammation in active sickle cell disease and atherosclerosis.

Rabbit Anti-Human PlGF (native)

102-PA04 100ug
EUR 240

Polyclonal Anti-PGF (PLGF) Antibody

GWB-BBP088 0.1 mg Ask for price

PlGF-2/PLGF/PGF Protein, Mouse

UA040136
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 5 µg
  • 10 µg
  • 50 µg
  • 100 µg
  • 500 µg
  • 1 mg

PlGF-1/PLGF/PGF Protein, Human

UA040142
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 5 µg
  • 10 µg
  • 50 µg
  • 100 µg
  • 500 µg
  • 1 mg

Rabbit Anti-Human PlGF (Peptide)

102-PA01 100ug
EUR 240

PLGF

E8ET1704-99 100ul
EUR 275
Description: Available in various conjugation types.

PLGF

E8EM1701-88 100ul
EUR 275
Description: Available in various conjugation types.

PLGF

E8EM1701-90 100ul
EUR 275
Description: Available in various conjugation types.

PLGF

E8ER1706-88 100ul
EUR 275
Description: Available in various conjugation types.

PLGF

MBS438326-002mgWithBSAAzideat02mgmL 0.02mg(WithBSA&Azideat0.2mg/mL)
EUR 230

PLGF

MBS438326-01mgWithBSAAzideat02mgmL 0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 405

PLGF

MBS438326-01mgWithoutBSAAzideat1mgmL 0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 405

PLGF

MBS438326-5x01mgWithBSAAzideat02mgmL 5x0.1mg(WithBSA&Azideat0.2mg/mL)
EUR 1725

PLGF

MBS438326-5x01mgWithoutBSAAzideat1mgmL 5x0.1mg(WithoutBSA&Azideat1mg/mL)
EUR 1725

PlGF

MBS517478-0025mg 0.025mg
EUR 290

PlGF

MBS517478-5x0025mg 5x0.025mg
EUR 1055

PLGF

MBS8535142-01mL 0.1mL
EUR 305

PLGF

MBS8535142-01mLAF405L 0.1mL(AF405L)
EUR 565

PLGF

MBS8535142-01mLAF405S 0.1mL(AF405S)
EUR 565

PLGF

MBS8535142-01mLAF610 0.1mL(AF610)
EUR 565

PLGF

MBS8535142-01mLAF635 0.1mL(AF635)
EUR 565

PLGF

MBS8565284-01mL 0.1mL
EUR 345

PLGF

MBS8565284-01mLAF405L 0.1mL(AF405L)
EUR 565

PLGF

MBS8565284-01mLAF405S 0.1mL(AF405S)
EUR 565

PLGF

MBS8565284-01mLAF610 0.1mL(AF610)
EUR 565

PLGF

MBS8565284-01mLAF635 0.1mL(AF635)
EUR 565

PLGF

MBS8565552-01mL 0.1mL
EUR 345

PLGF

MBS8565552-01mLAF405L 0.1mL(AF405L)
EUR 565

PLGF

MBS8565552-01mLAF405S 0.1mL(AF405S)
EUR 565

PLGF

MBS8565552-01mLAF610 0.1mL(AF610)
EUR 565

PLGF

MBS8565552-01mLAF635 0.1mL(AF635)
EUR 565

PLGF

MBS8564829-01mL 0.1mL
EUR 345

PLGF

MBS8564829-01mLAF405L 0.1mL(AF405L)
EUR 565

PLGF

MBS8564829-01mLAF405S 0.1mL(AF405S)
EUR 565

PLGF

MBS8564829-01mLAF610 0.1mL(AF610)
EUR 565

PLGF

MBS8564829-01mLAF635 0.1mL(AF635)
EUR 565

PLGF

MBS8564831-01mL 0.1mL
EUR 345

PLGF

MBS8564831-01mLAF405L 0.1mL(AF405L)
EUR 565

PLGF

MBS8564831-01mLAF405S 0.1mL(AF405S)
EUR 565

PLGF

MBS8564831-01mLAF610 0.1mL(AF610)
EUR 565

PLGF

MBS8564831-01mLAF635 0.1mL(AF635)
EUR 565

PLGF

PA1066 100μg
EUR 260

PLGF

PA1066-M 100μg
EUR 290
Description: Polyclonal Antibodies Conjugated to Magnetic Beads

PLGF

PA1066-S 100μg
EUR 290
Description: Polyclonal Antibodies Conjugated to Sepharose Beads

Sheep Polyclonal anti-human PlGF

hAP-5406 50ug
EUR 400

Mouse Monoclonal anti-human PlGF

hAP-0010 100ug
EUR 250

PlGF Antibody

5743-100 each
EUR 405.6

PlGF Antibody

5743-30T each
EUR 175.2

PLGF Antibody

49602 100ul
EUR 499

PLGF Antibody

49602-100ul 100ul
EUR 399.6

PLGF Antibody

49602-50ul 50ul
EUR 286.8

PLGF Antibody

GWB-628116 0.1 mg Ask for price

PLGF Antibody

E8RT1505 100ul
EUR 225
Description: Available in various conjugation types.

PLGF Antibody

MBS9436345-005mL 0.05mL
EUR 325

PLGF Antibody

MBS9436345-01mL 0.1mL
EUR 435
Furthermore, coculturing hiPSC-derived fibroblasts and keratinocytes constantly shaped organotypic 3D pores and skin equivalents. Due to this fact, keratinocytes generated by this technique are a viable supply of cells for downstream functions.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *